دورية أكاديمية
Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study.
| العنوان: | Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study. |
|---|---|
| المؤلفون: | Benz E; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Internal Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Wijnant SRA; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.; Dept of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium., Trajanoska K; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Internal Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Arinze JT; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.; Dept of Medical Informatics, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., de Roos EW; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium., de Ridder M; Dept of Medical Informatics, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Williams R; Dept of Medical Informatics, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., van Rooij F; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Verhamme KMC; Dept of Medical Informatics, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Ikram MA; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Stricker BH; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands., Rivadeneira F; Dept of Internal Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; These authors contributed equally., Lahousse L; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.; These authors contributed equally., Brusselle GG; Dept of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.; Dept of Respiratory Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.; These authors contributed equally. |
| المصدر: | ERJ open research [ERJ Open Res] 2022 Jan 10; Vol. 8 (1). Date of Electronic Publication: 2022 Jan 10 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Sheffield : European Respiratory Society, [2015]- |
| مستخلص: | Background: Increasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with COPD. However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD or asthma and all-cause mortality in a large-scale population-based setting. Methods: Between 2009 and 2014, 4482 participants (aged >55 years; 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were diagnosed clinically and based on spirometry. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, body mass index, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII, and mortality in these groups was compared. Results: Over a median follow-up of 6.1 years (interquartile range 5.0-7.2 years), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (hazard ratio (HR) 2.13, 95% CI 1.46-3.12 and HR 1.70, 95% CI 1.32-2.18 for those with and without sarcopenia, respectively). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma. Conclusion: Middle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma. Competing Interests: Conflict of interest: E. Benz has nothing to disclose. Conflict of interest: S.R.A. Wijnant reports grants from GlaxoSmithKline outside the submitted work. Conflict of interest: K. Trajanoska has nothing to disclose. Conflict of interest: J.T. Arinze reports a doctoral research grant from Merck Sharp & Dohme, paid to their institution, outside the submitted work. Conflict of interest: E.W. de Roos has nothing to disclose. Conflict of interest: M. de Ridder has nothing to disclose. Conflict of interest: R. Williams has nothing to disclose. Conflict of interest: F. van Rooij has nothing to disclose. Conflict of interest: K.M.C. Verhamme reports that they work for a research department that receives or has received unconditional grants from Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, GSK, UCB, Amgen and Chiesi, none of which are related to the content of this paper. Conflict of interest: M.A. Ikram has nothing to disclose. Conflict of interest: B.H. Stricker has nothing to disclose. Conflict of interest: F. Rivadeneira has nothing to disclose. Conflict of interest: L. Lahousse reports financial support for the current manuscript from the Fund for Scientific Research Flanders (grant 3G037618), and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Institute for Continuing Study of Pharmacists, outside the submitted work. Conflict of interest: G.G. Brusselle reports receiving fees for advisory boards or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi and Teva, outside the submitted work. (Copyright ©The authors 2022.) |
| References: | Clin Respir J. 2021 Apr;15(4):400-405. (PMID: 33249745) Am J Respir Crit Care Med. 2002 Sep 15;166(6):809-13. (PMID: 12231489) Front Physiol. 2017 Dec 12;8:1045. (PMID: 29311975) J Inflamm Res. 2021 Jan 18;14:131-140. (PMID: 33500649) Int J Chron Obstruct Pulmon Dis. 2017 Feb 20;12:669-675. (PMID: 28255238) Clin Cancer Res. 2014 Dec 1;20(23):6212-22. (PMID: 25271081) Age Ageing. 2013 Mar;42(2):203-9. (PMID: 23321202) Lancet Respir Med. 2017 Sep;5(9):691-706. (PMID: 28822787) Rev Esp Geriatr Gerontol. 2017 Nov - Dec;52(6):313-316. (PMID: 27639279) Oncotarget. 2017 Jun 29;8(43):75381-75388. (PMID: 29088873) Clin Nutr. 2020 Nov;39(11):3461-3466. (PMID: 32204975) Front Physiol. 2012 Jul 11;3:260. (PMID: 22934016) Int J Mol Sci. 2010 Apr 12;11(4):1509-26. (PMID: 20480032) ERJ Open Res. 2021 Mar 08;7(1):. (PMID: 33718493) Front Nutr. 2021 May 24;8:661449. (PMID: 34109204) Age Ageing. 2019 Jan 1;48(1):16-31. (PMID: 30312372) Eur Respir J. 2004 Jun;23(6):932-46. (PMID: 15219010) Eur Respir Rev. 2018 Feb 7;27(147):. (PMID: 29436405) PLoS Med. 2020 May 7;17(5):e1003115. (PMID: 32379748) Respir Med. 2020 Apr - May;165:105919. (PMID: 32174450) Respirology. 2021 Jan;26(1):62-71. (PMID: 32542761) Eur J Epidemiol. 1991 Jul;7(4):403-22. (PMID: 1833235) Ann Am Thorac Soc. 2016 Mar;13(3):334-41. (PMID: 26700501) Int J Cancer. 2020 Feb 1;146(3):692-698. (PMID: 30924141) J Am Med Dir Assoc. 2016 Aug 1;17(8):712-8. (PMID: 27161848) J Neuroinflammation. 2019 Mar 30;16(1):68. (PMID: 30927918) Int J Chron Obstruct Pulmon Dis. 2021 Feb 17;16:341-349. (PMID: 33633446) J Allergy Clin Immunol Pract. 2020 Jun;8(6):1828-1838. (PMID: 32499032) Sci Rep. 2021 Jun 15;11(1):12532. (PMID: 34131164) Adv Nutr. 2020 Jul 1;11(4):S1058-S1069. (PMID: 32666115) Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675) Medicina (Kaunas). 2020 Jul 29;56(8):. (PMID: 32751302) Respir Med. 2005 Aug;99(8):1004-9. (PMID: 15950141) Eur J Epidemiol. 2020 May;35(5):483-517. (PMID: 32367290) Eur Respir Rev. 2019 Nov 13;28(154):. (PMID: 31722892) Eur Respir J. 2019 Mar 18;53(3):. (PMID: 30886026) Am J Clin Nutr. 2005 Jul;82(1):53-9. (PMID: 16002800) Respir Med. 2018 Jun;139:6-12. (PMID: 29858003) |
| تواريخ الأحداث: | Date Created: 20220117 Latest Revision: 20220430 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8752940 |
| DOI: | 10.1183/23120541.00628-2021 |
| PMID: | 35036418 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2312-0541 |
|---|---|
| DOI: | 10.1183/23120541.00628-2021 |